Retina Institute Japan K.K., which employes Nobel Prize-winning stem-cell technology to treat eye diseases, plans to sell a stake in itself to a group of Japanese companies next month, ahead of a possible initial public offering in five years.
The company will raise ¥1 billion from the sale to fund development of a treatment for age-related macular degeneration — a leading cause of blindness in the elderly — using technology developed by the Riken research institute, Retina Chief Executive Officer Hardy Kagimoto said.
After raising about ¥32 billion so far from investors, Retina is developing technology from a discovery that jointly won Kyoto University professor Shinya Yamanaka the Nobel Prize in physiology or medicine in October for turning ordinary skin cells into induced pluripotent stem (iPS) cells.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.